APR 22, 2021 1:24 PM PDT

mRNA Covid Vaccines May Protect Against New Strains and Common Cold

WRITTEN BY: Annie Lennon

Researchers from Johns Hopkins have found that the mRNA Covid vaccines developed by Pfizer and Moderna not only work with the original strain of SARS-CoV-2, but also new variants, as well as the common cold. 

After receiving either vaccine the immune system produces CD4+ T lymphocytes, immune cells also known as helper T cells. These cells activate another type of immune cell known as B lymphocytes (B cells) which respond to surface proteins on cells infected by viruses including SARS-CoV-2. Once activated in this way, immature B cells either become plasma cells that produce antibodies that mark infected cells for disposal, or ‘memory cells’ that help the body recognize and react to the same antigens more quickly in future infections. 

For the study, the researchers examined blood samples from 30 healthy healthcare workers and lab donors who had not previously tested positive for COVID-19 before and after receiving a COVID-19 mRNA vaccine. They then withdrew CD4+ T cells from their blood samples and tested their response to protein fragments from the original SARS-CoV-2 spike protein as well as three common cold coronaviruses. 

In doing so, they identified 23 distinct T cell-targeted peptides. From these, only four were affected by the mutations seen in COVID variants from the United Kingdom and South Africa. As the other 19 peptides which are targeted by the vaccines are the same in both the original virus and the newer strains, the mRNA vaccines should theoretically induce T cells that respond to these variants too. 

The researchers say this means that the T cells induced by mRNA vaccines may prevent the variant viruses from causing severe cases of COVID-19 disease, even if they don’t prevent infection. They also noted that the vaccines led to a three-fold increase in CD4+ T cell responses to HCoV-NL63 spike peptides after vaccination, meaning that the vaccine should also work for a variant of the common cold. 

 

Sources: Medical XpressThe Journal of Clinical Investigation

About the Author
  • Science writer with a keen interest in behavioral biology, consciousness medicine and technology. Her current focus is how the interplay of these fields can create meaningful interactions, products and environments.
You May Also Like
JAN 13, 2021
Drug Discovery & Development
Antibody Can Target Dengue Viral Proteins
JAN 13, 2021
Antibody Can Target Dengue Viral Proteins
Researchers have found an antibody that can stop the spread of the dengue virus—a mosquito-borne pathogen that inf ...
JAN 16, 2021
Drug Discovery & Development
Alternative Pain-Relief Bio-patch
JAN 16, 2021
Alternative Pain-Relief Bio-patch
Researchers develop a bio-compatible patch that releases non-opioid painkillers for days and potentially serving as a sa ...
FEB 26, 2021
Microbiology
Good Bacteria Fights Bad Bacteria in a Clinical Trial
FEB 26, 2021
Good Bacteria Fights Bad Bacteria in a Clinical Trial
Eczema is a skin condition that causes a chronic, itchy rash. The most common form of the disorder, atopic dermatitis, i ...
FEB 25, 2021
Drug Discovery & Development
Future COVID-19 Targets Rapidly Identified with Computer Simulations
FEB 25, 2021
Future COVID-19 Targets Rapidly Identified with Computer Simulations
A recent mechanism as detailed in the novel SARS-CoV2 that causes COVID-19 could help scientists find new therapeutics. ...
MAR 04, 2021
Infographics
All You Need to Know about COVID-19 Vaccines
MAR 04, 2021
All You Need to Know about COVID-19 Vaccines
After over a year lockdowns brought on by the pandemic, hopes for returning to something even similar to ' ...
MAR 06, 2021
Genetics & Genomics
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
MAR 06, 2021
Green Tea Extract Can Affect Facial Development in Kids With Down Syndrome
Individuals with Down syndrome often have certain facial features. New research has suggested that green tea supplements ...
Loading Comments...